Trial Profile
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR) 10 MG ONCE DAILY OR MATCHING PLACEBO TO PREVENT THE DEVELOPMENT OF TOLERANCE TO BRONCHOPROTECTION AND BRONCHODILATION BY BETA-AGONISTS OCCURRING AFTER TWO WEEKS REGULAR TREATMENT WITH SALMETEROL (SEREVENT) 50microG B.I.D.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2011
Price :
$35
*
At a glance
- Drugs Montelukast (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms PREDATOR
- 31 May 2011 New trial record